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Specific B-cell tolerance toward donor blood group
antigens develops in infants after ABO-incompatible
heart transplantation, whereas their immune response
toward protein antigens such as HLA has not been in-
vestigated. We assessed de novo HLA-antibodies in
122 patients after pediatric thoracic transplantation
(28 ABO-incompatible) and 36 controls. Median age
at transplantation was 1.7 years (1 day to 17.8 year)
and samples were collected at median 3.48 years af-
ter transplantation. Antibodies were detected against
HLA-class I in 21 patients (17.2%), class II in 18 (14.8%)
and against both classes in 10 (8.2%). Using single-
antigen beads, donor-specific antibodies (DSAs) were
identified in six patients (all class II, one additional
class I). Patients with DSAs were significantly older
at time of transplantation. In patients who had under-
gone pretransplant cardiac surgeries, class II antibod-
ies were more frequent, although use of homografts
or mechanical heart support had no influence. DSAs
were absent in ABO-incompatible recipients and class
II antibodies were significantly less frequent than in
children with ABO-compatible transplants. This differ-
ence was present also when comparing only children
transplanted below 2 years of age. Therefore, tolerance
toward the donor blood group appears to be asso-
ciated with an altered response to HLA beyond age-
related effects.
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Introduction
Infants differ fundamentally in their capacity to mount im-
mune responses to polysaccharide antigens (i.e. blood
group antigens, ABO) versus protein antigens (i.e. HLA).
Because infants do not normally manifest responses to
foreign blood groups, ABO-incompatible heart transplanta-
tion was found to be a safe clinical approach to enhance
donor availability (1). After ABO-incompatible transplanta-
tion, a majority of recipients develop spontaneous B-cell
tolerance to the donor blood group antigens, showing a pat-
tern of persistent absence of antibodies toward the donor
blood group, whereas antibodies toward other polysaccha-
ride antigens, such as the nondonor blood group, develop
normally (2). An analysis of the underlying mechanisms of
tolerance in this setting demonstrated absence of active
B cells specific to the donor blood group (3). However,
immune responses also vary with age. Young animals re-
spond poorly if at all to challenge by certain antigens. More-
over, Medawar and colleagues demonstrated in the 1950s
that exposure of newborn animals to allogeneic cells in-
duced a state of specific immune tolerance to subsequent
antigen exposure in skin grafts (4). Whether and to what
extent acceptance of grafts by young recipients reflects im-
maturity and hence absence of responses, and to what ex-
tent it reflects tolerance, is poorly understood. We now ex-
plore how tolerance or immunologic immaturity may affect
responses to other donor antigens, such as HLA, proteins
to which human infants are normally capable of mounting
an immune response.
Anti-HLA antibodies are associated with hyperacute and
acute antibody-mediated rejection if present at the time
of transplantation (5). De novo antibodies that develop af-
ter transplantation have been shown to accelerate graft
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vasculopathy and lead to decreased graft survival in adults
after heart (6) and other solid organ transplants (7). In chil-
dren requiring heart transplantation, smaller studies have
described the same consequences, especially if the anti-
bodies were directed toward specific HLA present on the
donor organ (8,9). However, most of the available pediatric
data concern patients who were presensitized or whose
antibody status was unknown prior to transplantation.
The purpose of this study was to determine if children
after ABO-incompatible transplantation show differences
when compared to ABO-compatible recipients regard-
ing the presence and specificity of de novo anti-HLA
antibodies. We further assessed the influence of age
at transplantation and previously described risk factors
such as pretransplant cardiac surgery, use of surgically
implanted ‘homografts’ (10,11) and mechanical cardiac
support (12) on the posttransplant development of HLA-
antibodies. With the inclusion of a control group without
obvious sensitizing events such as prior surgery or trans-
fusion, we also investigated the development of ‘natural’
HLA-antibodies in children, which have been found in more
than 60% of healthy male adults (13).
Methods
The patient cohort was recruited in three pediatric thoracic transplant cen-
ters, Edmonton and Toronto, Canada, and Munich, Germany. In Canada,
patient plasma was collected within a study on cardiac transplant in infancy
after approval from the institutional ethical review boards and written in-
formed consent of each patient’s parents or guardians. The patients from
Munich underwent antibody screening as part of routine clinical follow-up.
Clinical data were collected within a follow-up database for thoracic trans-
plant patients with written consent of the patient’s parents or guardians and
approved by local ethical review board. The demographic, clinical and test
data were blinded for analysis.
Study subjects included patients after pediatric heart or heart–lung–
transplantation and a control group of otherwise healthy children with minor
cardiac disorders (atrial septal defect, patent arterial duct) who underwent
cardiac catheter examination without having had prior surgery or blood
transfusion and consented within the Canadian study protocol. The con-
trols were matched to the patient cohort by age, gender and blood group.
Patients with HLA-sensitization detected pretransplant with either cytotoxic
assays, ELISA or flow cytometry were excluded, as well as patients with
congenital immunodeficiency, chromosomal abnormalities or prior use of
B-cell–depleting antibodies (rituximab).
The plasma samples for antibody screening were frozen at −80◦C directly
after drawing and thawed in batches for immediate analysis. Antibody
screening was performed by flow beads (FlowPRA R©, One Lambda, Canoga
Park, CA) and enzyme-linked immunosorbent assay (ELISA; AbScreen R©
HLA class I and II Biotest, Dreieich, Germany; licensed and approved for clin-
ical use). Following manufacturers’ recommendations ELISA screen greater
than twice the mean of the negative controls was defined as positive.
A positive FlowPRA R© screen was defined as ≥5% or clear pattern of re-
activity with screening beads. Positive screens were further analyzed with
FlowPRA R© Single Antigen I and II beads (One Lambda). Manufacturer’s
instructions for staining and acquiring were followed. Beads were analyzed
on a BD FACSCaliburTM cytometer (Becton Dickinson Biosciences, Missis-
sauga, Ontario, Canada). Single-antigen beads were used to test for anti-
bodies against HLA-A, HLA-B, DRB1, DRB3, DRB4 and DRB5 and DQB1. As
the patients included in the study were transplanted since 1989, methods
of pretransplant HLA typing improved over time and breadth of tested HLA
antigens increased. We therefore limited the analysis for donor specificity
to the generally available loci HLA-A, HLA-B and DR.
Statistical analysis was performed using Sigma Plot R©/Sigma Stat R© and
SPSS R©. Not all variables followed a normal distribution. Therefore, quanti-
tative values were analyzed using Mann–Whitney rank sum test for compar-
ison of two groups and Kruskal–Wallis test for comparison of more than two
groups. Qualitative parameters were compared using z-test, v 2 or Fisher’s
exact test; correlations were determined using linear regression and Spear-
man correlation. To exclude confounding effects of the young age at trans-
plantation, a separate analysis was performed comparing ABO-incompatible
recipients to an age-matched group of ABO-compatible recipients.
Results
Patient characteristics
The demographic and clinical history of the patient cohort
is shown in Table 1. A total of 122 patients were included,
of whom about half were transplanted in the first 2 years of
life. This relatively young group appears representative for
the demographic structure in many pediatric heart trans-
plant centers (14,15). Table 2 compares clinical data of
children who received ABO-incompatible versus compat-
ible transplantation younger than 2 years of age. There
were no significant differences regarding immunosuppres-
sive medication or target trough levels at time of sample
collection, or presence of any type of induction treatment.
There was no significant difference in immunosuppressive
treatment comparing patients with versus without class
I, class II or donor-specific HLA-antibodies. The standard
maintenance treatment in all participating centers was
tacrolimus combined with mycophenolate mofetil, with
Table 1: Demographic and clinical characteristics of the patients
Type of tranplantation
Heart ABO compatible 86 (70%)
Heart ABO incompatible 28 (23%)
Heart–lung 8 (7%)




and sample collection (median
and range, years)
3.48 (0.6–17.1)
Age of control group at sample





Congenital heart disease 53 (43%)
Myocarditis 5 (4%)
Primary pulmonary hypertension 4 (3%)
Kawasaki disease 1 (1%)
Other/unknown 5 (4%)
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Table 2: Comparison of clinical and technical aspects comparing all patients versus patients transplanted in the first 2 years ABO
incompatible or compatible
All ABOi ABOc <2 years
No. of patients 122 28 37
HLA mismatch (mean ± SD) Class I (A/B) mismatch 3.1 ± 0.83 2.9 ± 0.89 3.2 ± 0.81
Class II (DR) mismatch 1.5 ± 0.65 1.6 ± 0.53 1.5 ± 0.52
No mismatch A/B 0 0 0
No mismatch DR 1.60% 0 0
Immunosuppressive medication
Current maintenance (% of patients) Tacrolimus 85.2 89.3 82.4
Cyclosporine A 9.8 10.7 14.7
Mycophenolate 69.7 59.3 75.0
Azathioprine 7.4 11.1 9.4
Sirolimus 4.1 3.6 0
Everolimus 1.6 0 2.9
Low-dose steroids 14.8 21.4 7.7
Induction (% of patients) Any induction 73.8 100 75.7
ATG 56.6∗ 100∗ 64.9∗
IL-2 receptor-antibody 17.2 0 10.8
None 25.4∗ 0∗ 21.6∗
Method of antibody screening Flow-PRA 54.1 85.7 67.6
ELISA 40.2 10.7 29.7
Both 5.7 3.6 2.7
Similar regimens for immunosuppressive therapy except for significantly more frequent use of ATG-induction in children with ABOi
transplantation ∗(p < 0.05). No significant differences in HLA-mismatch and used antibody-screening method.
steroids over the first 6–12 months in weaning doses. Indi-
vidual patients received different medications for particular
clinical reasons. All ABOi-transplanted children received in-
duction with commercial or generic polyclonal antithymo-
cyte globulin (ATG), which was standard treatment in the
Canadian centers for all patients with only single patients
excepted. In Munich, induction with polyclonal antibodies
was not standard for ABO-compatible transplantation but
rather anti-CD25 antibodies (daclizumab, basiliximab) or no
specific induction, whereas all ABOi-transplanted children
received ATG following the Toronto protocol. Therefore,
ABOi-transplanted children were significantly more likely
to have received ATG for induction. The use of ATG, how-
ever, was not associated with a lower or higher presence
of HLA-antibodies of either class in the cohort.
HLA-mismatch is only shown for HLA-A, HLA-B and DR
antigens, as typing for other loci (e.g. Cw and DQ) was
only performed in the more recently transplanted children;
there were no differences between the groups. The trend
to use FlowPRA more frequently for testing of younger and
ABOi-transplanted children was not significant.
Frequency of de novo HLA-antibodies among thoracic
transplant recipients and healthy children
In samples from 60 patients (48.8%) and all 36 controls,
HLA-antibodies were analyzed by ‘flow beads’, whereas
ELISA assays were used for samples from 55 patients
(45.6%), and both methods for seven patients (5.7%).
Anti-HLA antibodies were detected in 29 of 122 patients
(23.8%). Of these, 21 patients (17.2%) had antibodies
against HLA class I and 18 (14.8%) had antibodies against
HLA class II. The presence of antibodies against class I
antigens significantly correlated with presence of antibod-
ies against class II (p < 0.01): 11 patients had antibodies
against class I only, 8 against class II only and 10 against
both classes. Donor-specific de novo antibodies (DSAs)
were found in six patients (4.9%) all against class II, and in
one patient additionally against class I. Patients with DSAs
were significantly older at transplantation than subjects
lacking those antibodies (p < 0.05). The distribution of age
at transplant comparing patients with HLA-antibodies ver-
sus without is shown in Figure 1. No patient transplanted in
the first 30 months of age had detectable DSAs, whereas
antibodies against nondonor antigens were present in the
same proportion as in patients transplanted later in life. As
shown in Figure 2, these differences in immune responses
were not owed to differences in the interval between trans-
plantation and sample collection.
During the period of time in which these patients were
followed, graft survival was not significantly influenced by
the presence of de novo HLA-antibodies (Figure 3). Pa-
tients with antibodies specific for HLA class II do exhibit
what appears to be lower survival after 10 years, however
the number of patients followed for this period of time is
too few to exclude chance as the basis for the difference.
The 10-year survival was above 90% in all patients.
In the control group of 36 healthy children, seven (19.4%)
had detectable anti-HLA antibodies. Of these, four (11%)
had antibodies specific only for HLA class I, two (6%) only
for HLA class II and one (3%) for both. Age distribution
of positive and negative findings is shown in Figure 4. Al-
though class I-directed antibodies were found throughout
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Figure 1: Age at transplantation versus presence of antibod-
ies: Distribution of age at transplantation of all patients and pa-
tients with class I, class II and donor-specific antibodies. The box
represents 25th, 50th and 75th percentile, the whiskers indicate
10th and 90th percentile, the circles show the 5th and 95th per-
centile, the dotted line represents the mean. Patients with donor-
specific antibodies were significantly older at transplantation than
the whole cohort (p < 0.05).
childhood beginning as early as 26 days of life, the youngest
patient with class II antibodies was 5.7 years old.
Influence of risk factors for HLA sensitization
in thoracic transplant recipients
The groups with class I, class II and donor-specific antibod-
ies (DSAs) were analyzed for the presence of previously
described risk factors for HLA sensitization. We found no
significant influence of ‘homograft’ implantation and of
Figure 2: Interval post transplantation versus presence of an-
tibodies: Interval between transplantation and sample collection
comparing all patients and patients with class I, class II and donor-
specific antibodies. The box represents 25th, 50th and 75th per-
centile, the whiskers indicate 10th and 90th percentile, the circles
show the 5th and 95th percentile, the dotted line represents the
mean. No significant difference between the groups.
ventricular assist devices (VADs) or extracorporeal mem-
brane oxygenation (ECMO) (Figure 5). Pretransplant car-
diac surgery was more common in the group with class II
antibodies (Figure 5) but this observation did not reach sta-
tistical significance (p = 0.075). Comparing patients with
pretransplant cardiac surgery toward those without, we
found a highly significant difference (p < 0.001): class II-
specific antibodies were present in nine of 40 patients
(22.5%) with surgery but only in seven of 79 (9.1%) with-
out. Occurrence of class I antibodies was not significantly
different regarding presence versus absence of pretrans-
plant surgery.
Influence of blood group compatibility on production
of anti-HLA antibodies
To determine whether and how ABO-incompatibility be-
tween donor and recipient might influence anti-HLA re-
sponses, the patient cohort was analyzed for presence
or absence of anti-HLA antibodies by ABO-compatibility
status. Antibodies to HLA class II were present signifi-
cantly less frequently (p < 0.05) in patients after ABO-
incompatible transplantation than after ABO-compatible
transplantation (Figure 6). Class I-specific antibodies were
present in about the same proportion in both groups. DSAs
were completely absent in all 28 ABO-incompatible recipi-
ents (p < 0.01 compared to ABO-compatible). As all ABO-
incompatible transplants were performed within the first
24 months of life, we compared them to the identical age
group of ABO-compatible recipients. Although class II an-
tibodies were significantly rarer in the ABO-incompatible
group (p < 0.05), DSAs were also absent in all ABO-
compatible recipients transplanted in the first 2 years of
life.
Discussion
This is the first study investigating the development of de
novo HLA-antibodies in children after ABO-incompatible
heart transplantation, and addressing the potential differ-
ences in the development of anti-HLA antibodies follow-
ing thoracic transplantation in early versus later childhood.
Whereas previous studies in children did not focus on
presence of de novo HLA-antibodies, we have analyzed
a unique patient group by excluding children who were
sensitized prior to transplantation. We have found that pa-
tients developing DSAs were significantly older at trans-
plantation than those who did not. The DSAs in all our
patients were directed against class II antigens, with ad-
ditional class I-specific DSAs in only one patient. This may
be of some importance regarding the immunologic func-
tion of class II HLA molecules as they are a crucial part
of the indirect pathway of antigen presentation. Whereas
HLA class I molecules are present on nearly all cells
and can be directly recognized by antigen-specific CD8+
T cells (16), class II molecules are required for specific
antigen presentation. Thus, immaturity in indirect antigen
presentation may contribute to this difference in immune
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Figure 3: Graft survival: Kaplan–Meier survival curves comparing graft survival in patients with versus without antibodies against
HLA-class I, HLA-class II and donor-specific HLA. No significant difference in survival (Gehan–Breslowtest p > 0.05).
responses of early childhood. In the heart, HLA class II ex-
pression is found predominantly on vascular endothelium
(17) whereas cardiomyocytes show only weak expression
of both HLA classes (18). In addition to vascular endothe-
lium, expression of HLA class II molecules is generally
limited to highly specialized cells of the immune system
such as macrophages, dendritic cells and B cells (19).
In this context, the role of B cells as specific antigen-
presenting cells, in addition to their function as a main
component for initiation of antibody-mediated rejection
(20), may be crucial. The interaction of B and T cells has
been found to be less efficient in early childhood than
later, for example as in reduced expression of CD40 and
CD40 ligand (CD154) (21). Studies on infection and vacci-
Figure 4: Presence of HLA-antibodies and age distribution of
in the control group: Presence of HLA-specific antibodies in the
group of 36 matched controls versus age at sample collection.
HLA-class II antibodies (white triangles) were present only in pa-
tients more than 5 years old, while class I were found as early as
the first months of life.
nation have further demonstrated that early childhood im-
munity is skewed toward a less persistent cell-mediated
and more prominent Th2 immune response. Despite these
elements of immunologic immaturity, human infants are
known to be sufficiently competent to mount a vigorous
and broad HLA-antibody response to implanted vascular
allograft tissue patches when not pharmacologically im-
munosuppressed (10,11). Thus, our results suggest that
the immune response to a transplanted organ in infancy,
under systemic immunosuppression, may be less likely to
lead to specific antibody production than when transplan-
tation is performed later in life. This impairment of specific
antibody production could, in part, explain the observation
of the far better long-term survival of children transplanted
at an early age when compared to patients transplanted at
any later age (15).
The influence of young age on the absence of especially
class II antibodies was further confirmed by our control
group: while prevalence of HLA-antibodies overall was
lower than reported in adults, class II antibodies were
found exclusively in children older than five years. ‘Natural’
HLA-antibodies are speculated to develop following intra-
intestinal exposure to mimicry antigens (13). The lower in-
cidence of these antibodies in our pediatric control cohort
than described for adults might therefore either be due to
lack of exposure to the particular organisms or be due to
differences in the immune response in early childhood.
In unique contradistinction to these generalizable aspects
of T-dependent B-cell immunity related to transplantation
in infant recipients, the most striking finding in our patient
cohort is the significantly lower presence of HLA class II an-
tibodies and absence of DSAs following ABO-incompatible
heart transplantation compared to ABO-compatible. The
new clinical approach to infant transplantation afforded by
use of ABO-incompatible donors is an extrapolation of the
knowledge of general B-cell immaturity in early childhood,
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Figure 5: Presence of risk factors
in patients with and without HLA-
antibodies: Presence of pre-described
risk factors comparing all patients and
patients with class I, class II and
donor-specific antibodies (% of patients).
High prevalence of pretransplant cardiac
surgery in patients with class II antibod-
ies statistically not significant (p = 0.075).
and is largely limited to children in the first year or two of
life. This age group is known to have an impaired immune
response toward pure polysaccharide antigens, leading to
high susceptibility to infections with encapsulated bacteria
Figure 6: Influence of ABO compatibility on presence of
HLA-antibodies: Presence of HLA antibodies comparing ABO-
incompatible heart transplant recipients with ABO-compatible re-
cipients of all ages, and ABO-compatible recipients transplanted
within the first 24 months of life (% of patients). Difference signif-
icant for HLA-class II-specific antibodies in both of these groups
(p < 0.05). DSA were absent in all patients transplanted in the first
24 months of life regardless of ABO-compatibility.
and particularly severe courses of these infections (22). Be-
yond the lack of hyperacute and acute antibody-mediated
rejection such as described in ABO-incompatible transplan-
tation in older individuals, recipients of ABO-incompatible
heart grafts at this immature stage of immune develop-
ment show long-term absence of antibodies toward the
donor blood group (2,23). This was shown to be a form
of tolerance, represented by absence of antigen-specific
active B cells in patients’ peripheral blood (3) and con-
firmed by equivalent long-term clinical outcomes when
compared to ABO-compatible transplantation of the same
demographics. The timing and environment of B-cell ex-
posure to polysaccharide antigens seem to play a crucial
role in the balance of the immune system toward immu-
nity versus tolerance to a specific antigen (24), as well
as the interplay of B cells with the innate immune sys-
tem, especially complement components (25). The lack
of response to polysaccharide vaccines in early childhood
has been overcome by the creation of conjugate vac-
cines that connect the polysaccharide to a protein com-
ponent (26). It is not well understood why the activation of
T cells against the protein stimulates the B-cell response
to the connected polysaccharide but it was proven to be
highly efficient (27), even when the sensitized B-cell later
encounters the polysaccharide antigen without the pro-
tein. A possible explanation for our findings could be that
the observed B-cell tolerance or anergy toward the donor
blood group in ABO-incompatible recipients may in reverse
manner modulate the response to donor HLA, in particu-
lar toward class II antigens. This hypothesis needs to be
explored in experimental assays and may be unique to
the setting of suppressed immune function posttransplant.
There were no significant differences in the immunosup-
pressive treatment of the ABOi-transplanted children re-
garding maintenance immunosuppression as determined
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at the time of sample collection and use of any induction
treatment. ATG induction was more common in the ABOi-
transplanted group and could therefore be a confounding
event. However, this is not supported by the fact that ATG
induction was not associated with a difference in the oc-
currence of de novo HLA-antibodies in the overall patient
cohort.
Surprisingly, neither the use of homografts nor of VAD or
ECMO was found to be a relevant risk factor for develop-
ment of de novo antibodies in our cohort. This is most likely
due to the exclusion of presensitized patients in whom
these risk factors are often present, as these patients typ-
ically develop antibodies early after the intervention and
therefore prior to transplantation (10–12). Although some
of the earlier patients in our cohort may have been pre-
sensitized, with HLA-antibodies that might have been de-
tected with the more sensitive methods which were not
available at the time of pretransplant screening, the ma-
jority of patients were transplanted after 2003, when solid
phase assays were standard for pretransplant screening in
the participating centers. The higher prevalence of class II
antibodies after pretransplant surgery may indicate a sub-
clinical sensitization that becomes manifest later on. This
hypothesis is supported by the fact that these antibodies
were predominantly not donor specific. The mechanism of
sensitization following cardiac surgery is not perfectly de-
termined and most likely a combination of different factors:
activation of the immune system by the artificial surfaces
of the heart–lung machine (12), need for blood-transfusion,
mandatory because the small blood volume of young chil-
dren does not allow pump priming with patient blood, and
finally activation of the immune system by the massive
intervention and subsequent healing process.
In our cohort, we did not find a significant detrimental ef-
fect of de novo HLA-antibodies on graft survival. Although a
high incidence of graft vasculopathy has been observed in
patients with DSAs, this aspect was not systematically an-
alyzed in all patients in our cohort and therefore cannot be
judged. In adults, several studies have demonstrated a neg-
ative impact of class II and DSAs on graft survival, however
in children there are very few published data (28). A study
by Stastny et al. (9) addressed this question and did not
show a significant negative impact of de novo antibodies in
children, in contrast to the presence of antibodies prior to
transplant. However, their cohort was markedly older than
ours and had an unusually low overall survival. A second
study of a pediatric cohort also found no significant nega-
tive effect when separately analyzing the presence of de
novo antibodies (8). A recently presented analysis of data
from the UNOS database showed significant influence of
the antibody status (29), however this was not confirmed
by other reports (30). All these investigations are hampered
by the same limitations as our study: the low prevalence of
de novo antibodies in patients after pediatric thoracic trans-
plantation and the small number of patients in the long-
term follow-up groups. Whether graft accommodation has
occurred in these patients is unclear, particularly in relation
to possible protective effects mediated by persistent ex-
posure to low levels of antidonor antibodies. A further lim-
itation of our study is the use of different antibody assays
at different centers, as the flow-based assays are more
sensitive than older cell-based assays (31,32) and require
further evaluation of their clinical impact. The control group
was only analyzed using the more sensitive FlowPRA R©, so
the presence of natural antibodies may be overestimated
in comparison to the patient cohort. The characteristics of
the patient groups analyzed with the different assays were
not significantly different. However, as samples from most
of the younger patients and all but two ABO-incompatible
transplanted patients were analyzed by FlowPRA R©, any
potential bias would have pointed in the opposite direction
than our results. Further, due to the evolution of methods
and practices for HLA-typing in the donors and recipients,
many of the donors did not have typing at Cw and DQ,
and DP typing is not currently standard practice. Testing
for donor specificity therefore did not include HLA Cw
and HLA DP. Consequently, some DSAs may remain un-
detected, as well as antibodies against non-HLA epitopes.
In summary, this study has demonstrated that generation
of de novo anti-HLA antibodies following pediatric thoracic
transplantation is clearly age dependent. Whether the ab-
sence of antibodies in patients transplanted at a younger
age is due to combined effects of antigen exposure dur-
ing immunologic immaturity and concomitant systemic
immunosuppression, or due to other factors, remains un-
clear. Beyond this age-related phenomenon, infant recipi-
ents of ABO-incompatible heart transplants, in particular,
not only develop B-cell tolerance to donor ABO antigens
as previously described, but were found in this study also
to show reduced development of antibodies specific for
class II HLA, including DSAs. Understanding the underly-
ing mechanisms behind these results could give access
to new strategies to exploit inherent immaturities of the
infant immune system to improve transplant outcomes.
Moreover, mechanistic understanding of these physiologic
events may allow approaches to be developed to avoid or
to treat the major threat of long-term survival following or-
gan transplantation: antibody-mediated acute and chronic
rejection. Although our findings provide another piece of
evidence that ABO-incompatible heart transplantation in
early childhood is noninferior, one could even postulate a
benefit of this approach in terms of long-term antibody de-
velopment. However, the limited number of patients and
follow-up time prohibit such extensive conclusions until our
findings are confirmed by further studies including larger
patient numbers.
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